EcoDrugPlus

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSEEEG00000004662
Gene Symbol: CHRNA4B
4 Cross references
195 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSEEEG00000006874
Gene Symbol: F2R
4 Cross references
211 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSEEEG00000017002
Gene Symbol: F3
4 Cross references
171 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSEEEG00000011306
Gene Symbol: F3A
4 Cross references
199 Possible Orthologues:

Coiled-Coil Domain Containing 6a

Ensembl ID : ENSEEEG00000012727
Gene Symbol: CCDC6A
4 Cross references
208 Possible Orthologues:

Coiled-Coil Domain Containing 6b

Ensembl ID : ENSEEEG00000001943
Gene Symbol: CCDC6B
4 Cross references
151 Possible Orthologues:

Collagenase 3

Ensembl ID : ENSEEEG00000010597
Gene Symbol: LOC113580718
3 Cross references
173 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSEEEG00000010614
Gene Symbol: LOC113580721
4 Cross references
304 Possible Orthologues:

Colony Stimulating Factor 1 Receptor, A

Ensembl ID : ENSEEEG00000014776
Gene Symbol: CSF1RA
2 Cross references
207 Possible Orthologues:

Colony Stimulating Factor 1 Receptor, B

Ensembl ID : ENSEEEG00000013155
Gene Symbol: CSF1RB
3 Cross references
201 Possible Orthologues:

Complement Factor D (Adipsin)

Ensembl ID : ENSEEEG00000020429
Gene Symbol: CFD
4 Cross references
134 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSEEEG00000008179
Gene Symbol: CRHR1
4 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).